We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation.
- Authors
Čepulytė, Rūta; Žučenka, Andrius; Pečeliūnas, Valdas
- Abstract
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib.
- Subjects
MULTIPLE myeloma; MITOGEN-activated protein kinases; PROTEIN kinase inhibitors; PLASMA cells
- Publication
Case Reports in Hematology, 2020, p1
- ISSN
2090-6560
- Publication type
Article
- DOI
10.1155/2020/8894031